UK biotech hands off mid-stage C. dif­fi­cile drug in up to $570M deal

A biotech in the UK has out-li­censed a C. dif­fi­cile can­di­date to a US biotech for fur­ther clin­i­cal and com­mer­cial­iza­tion ef­forts.

UK-based Des­tiny Phar­ma an­nounced Fri­day that it is hand­ing NTCD-M3 to Se­bela Phar­ma­ceu­ti­cals. The deal in­cludes an ini­tial $1 mil­lion up­front, $19 mil­lion in de­vel­op­ment mile­stones, and an ad­di­tion­al $550 mil­lion in sales mile­stones — on top of roy­al­ties.

The deal al­lows Se­bela to lead and fi­nance clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion of the drug in North Amer­i­ca, while Des­tiny re­tains the ma­jor­i­ty of rights in Eu­rope and the rest of the world. Des­tiny added in a state­ment that Se­bela “has a mi­nor­i­ty in­ter­est in any in­come gen­er­at­ed in these non-North Amer­i­can ter­ri­to­ries based on the clin­i­cal stud­ies it is fund­ing.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.